Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field

Also Has Potential In AMD

 
• By Andrew McConaghie

Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.

Ionis HQ
Roche will lead the Phase III development of the therapy, based on Ionis' antisense drug platform. • Source: Ionis

More from Deals

More from Business